Drug Trial Radar · NCT07277660
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
165
Actual
Start
Dec 29, 2025
Primary completion
May 17, 2027
Study completion Mar 6, 2028
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Dec 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).
Conditions
- Atopic Dermatitis
Interventions
GalvokimigBiological
Drug: Galvokimig Pharmaceutical form: Solution for injection
PlaceboDrug
Drug: Placebo Pharmaceutical form: Solution for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with Eczema Area and Severity Index (EASI)75 response at Week 16Time frame: Week 16
Locations
59 sites in 9 countries. Site status is shown where the registry gives one.
Atd002 52021
Oceanside, California
Atd002 52008
Santa Monica, California
Atd002 52013
Boca Raton, Florida
Atd002 52007
Miami, Florida
Atd002 52003
Miami, Florida
Atd002 52015
Savannah, Georgia
Atd002 52017
Chicago, Illinois
Atd002 52018
Wheaton, Illinois
Atd002 52012
New Albany, Indiana
Atd002 52014
Bowling Green, Kentucky
Atd002 52009
Troy, Michigan
Atd002 52010
Omaha, Nebraska
Atd002 52022
New York, New York
Atd002 52020
The Bronx, New York
Atd002 52019
Philadelphia, Pennsylvania
Atd002 52005
Dallas, Texas
Atd002 52016
Frisco, Texas
Atd002 52011
Frisco, Texas
Atd002 52004
Sugar Land, Texas
Atd002 41004
Lovech, Bulgaria
Atd002 41001
Pleven, Bulgaria
Atd002 41007
Plovdiv, Bulgaria
Atd002 41002
Sevlievo, Bulgaria
Atd002 41005
Sofia, Bulgaria
Atd002 41006
Sofia, Bulgaria
Atd002 51002
Edmonton, Canada
Atd002 51006
Hamilton, Canada
Atd002 51007
Toronto, Canada
Atd002 51003
Vancouver, Canada
Atd002 42002
Náchod, Czechia
Atd002 42001
Prague, Czechia
Atd002 42003
Prague, Czechia
Atd002 42004
Prague, Czechia
Atd002 42005
Prague, Czechia
Atd002 43001
Bad Bentheim, Germany
Atd002 43004
Leipzig, Germany
Atd002 43007
Mahlow, Germany
Atd002 44001
Debrecen, Hungary
Atd002 21001
Habikino, Japan
Atd002 21007
Nagoya, Japan
Showing 40 of 59 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.